T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors

Leukemia. 1995 Jun;9(6):1006-12.

Abstract

In vitro culture of T lymphocytes infiltrating solid tumors has resulted in populations with significant, and sometimes selective, anti-tumor activity. In this study we evaluated the ability of T lymphocyte populations generated from the marrow of patients with chronic myelogenous leukemia (CML) to suppress autologous hematopoietic progenitors. T lymphocyte populations were obtained by culture of CML bone marrow mononuclear cells (BMMNC) with low dose rIL-2 (25 U/ml) after initial PHA stimulation, and restimulation during culture with autologous marrow cells. Preincubation of the cultured CML T lymphocytes in close contact with autologous BMMNC resulted in significant, dose-related suppression of autologous CFU-MIX and BFU-E colonies (P < 0.001). Close contact between effectors and targets was important for progenitor suppression. Progenitor suppression was mediated by CD4-positive T lymphocytes. In contrast to the significant suppression of autologous progenitors by CML T lymphocytes, T lymphocytes from normal bone marrow did not suppress autologous progenitors. We conclude that T lymphocyte populations with significant autologous progenitor suppressing ability can be generated from CML marrow. These observations may be of therapeutic value in CML.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antigens, CD / analysis
  • Bone Marrow / immunology*
  • Bone Marrow / pathology
  • CD4-Positive T-Lymphocytes / immunology
  • Cells, Cultured
  • HLA-DR Antigens / analysis
  • Hematopoietic Stem Cells / immunology*
  • Hematopoietic Stem Cells / pathology
  • Humans
  • Immune Tolerance
  • Immunophenotyping
  • Interleukin-2 / pharmacology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Lymphocyte Activation
  • Lymphocyte Depletion
  • Recombinant Proteins / pharmacology
  • Reference Values
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / pathology

Substances

  • Antigens, CD
  • HLA-DR Antigens
  • Interleukin-2
  • Recombinant Proteins